Background: Reference intervals (RIs) for serum IgG subclasses vary greatly among different geographical regions. The present study aimed to establish RIs for serum IgG subclasses in Chinese children, which is essential for interpretation of laboratory findings and making clinical decisions.

Methods: This study was performed in accordance with guideline C28-A3, proposed by the International Federation of Clinical Chemistry and the Clinical and Laboratory Standards Institute. In total, 607 apparently healthy Chinese children were enrolled, and serum levels of IgG subclasses were measured. Individuals were stratified by age and the RIs were determined through statistical analysis.

Results: Following were the median values of RIs for serum IgG subclasses in Chinese children: IgG1, 2.78 g/L; IgG2, 0.85 g/L; IgG3, 0.13 g/L; IgG4, 0.06 g/L at 1-6 months of age; IgG1, 3.64 g/L; IgG2, 0.73 g/L; IgG3, 0.19 g/L; IgG4, 0.03 g/L at 6-12 months of age; IgG1, 5.15 g/L; IgG2, 0.87 g/L; IgG3, 0.19 g/L; IgG4, 0.07 g/L at 1-2 years of age; IgG1, 5.26 g/L; IgG2, 1.23 g/L; IgG3, 0.14 g/L; IgG4, 0.11 g/L at 2-3 years of age; IgG1, 6.33 g/L; IgG2, 1.8 g/L; IgG3, 0.2 g/L; IgG4, 0.21 g/L at age 3-4 years; IgG1, 7.05 g/L; IgG2, 1.87 g/L; IgG3, 0.25 g/L; IgG4, 0.29 g/L at 4-6 years of age; IgG1, 6.19 g/L; IgG2, 1.93 g/L; IgG3, 0.2 g/L; IgG4, 0.28 g/L at 6-9 years of age; IgG1, 6.76 g/L; IgG2, 2.29 g/L; IgG3, 0.27 g/L; IgG4, 0.37 g/L at 10-12 years of age; IgG1, 7.45 g/L; IgG2, 2.92 g/L; IgG3, 0.28 g/L; IgG4, 0.38 g/L at 13-16 years of age.

Conclusion: To our knowledge, this study is the first to establish RIs for serum IgG subclasses exclusively in Chinese children.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5837086PMC
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0192923PLOS

Publication Analysis

Top Keywords

g/l
36
g/l igg2
36
g/l igg3
36
g/l igg4
36
age igg1
28
igg subclasses
24
serum igg
20
chinese children
20
years age
20
ris serum
16

Similar Publications

The capacity of government agencies to develop effective policy responses to external shocks is an important area of focus for health policy processes, as illustrated by the COVID-19 pandemic. However, few empirical studies exploring sub-national capacity of governments and the influence of institutional, organizational and political factors in shaping the policy response to complex emergencies have been conducted. The purpose of this study is to examine the governance capacity to develop and implement a policy response to a major health emergency-COVID-19-in Tamil Nadu, India, and to understand the factors shaping governance capacity during the first and second waves (2020-2021).

View Article and Find Full Text PDF

Background: There are little data on the use of smartphone-based applications for medication adherence and risk-factor control for the secondary prevention of stroke in low-and-middle-income countries (LMICs).

Aims: The aim was to determine whether a smartphone-based app improved medication adherence, risk-factor control, and provided health education to stroke survivors for lifestyle and behavioral modifications.

Methods: An unblinded, single-center randomized controlled double arm trial with 1:1 allocation among stroke survivors was performed in South India.

View Article and Find Full Text PDF

The role of antiplatelet therapies on incidence and mortality of hepatocellular carcinoma.

Eur J Clin Invest

January 2023

Gastroenterology Unit, Department of Internal Medicine, IRCCS Ospedale Policlinico San Martino, University of Genoa, Genoa, Italy.

Aim: To evaluate the impact of antiplatelet therapy (APT)on the incidence of hepatocellular carcinoma (HCC) and mortality following its treatment.

Methods: A systematic literature search was performed using PubMed and Cochrane Central Register of Controlled Trials Databases. Two HCC clinical settings were explored: (i) incidence, and (ii) death after any HCC treatment.

View Article and Find Full Text PDF

Drug repurposing is an alternative avenue for identifying new drugs to treat tuberculosis (TB). Despite the broad-range of anti-tubercular drugs, the emergence of multi-drug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis (Mtb) H37Rv, as well as the significant death toll globally, necessitates the development of new and effective drugs to treat TB. In this study, we have employed a drug repurposing approach to address this drug resistance problem by screening the drugbank database to identify novel inhibitors of the Mtb target enzyme, DNA gyrase.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!